Welcome to our dedicated page for Coherus Bioscien news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Bioscien stock.
Coherus BioSciences (NASDAQ: CHRS) is a commercial-stage biopharmaceutical company advancing innovative oncology therapies, including immunotherapies and biosimilars. This page provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping cancer care.
Discover comprehensive coverage of CHRS news, including FDA approvals, partnership announcements, and pipeline advancements. Our curated updates ensure you stay informed about the company activities that matter most—from late-stage clinical trials to commercialization strategies for oncology biosimilars.
Key focus areas include updates on immuno-oncology candidates targeting tumor microenvironments, progress in expanding global biosimilar access, and analyses of strategic collaborations. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for direct access to Coherus BioSciences' latest press releases and news. Check back regularly for authoritative insights into one of oncology’s most dynamic innovators.
Coherus BioSciences (NASDAQ: CHRS) will present final Phase 2 clinical trial data for casdozokitug (casdozo) at ASCO-GI 2025. The study evaluated casdozo, an IL-27-antagonistic antibody, in combination with atezolizumab and bevacizumab for treating metastatic hepatocellular carcinoma (HCC).
The company has initiated a new randomized Phase 2 study (NCT06679985) testing casdozo with bevacizumab and toripalimab in first-line HCC patients. This study will enroll up to 72 patients to evaluate safety, efficacy, and Project Optimus dosing of the triplet combination.
Previous Phase 3 HEPATORCH study results showed toripalimab with bevacizumab achieved 25.3% objective response rate versus 6.1% for sorafenib, with median overall survival of 20 months versus 14.5 months.
Coherus BioSciences (NASDAQ: CHRS) has agreed to sell its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, including $483.4 million upfront and $75 million in potential sales milestones. The company will use the proceeds to repay $230 million in convertible notes and $49.1 million in royalty obligations. Post-divestiture, Coherus will focus exclusively on its immuno-oncology portfolio, particularly LOQTORZI, an FDA-approved PD-1 inhibitor, and development of combination therapies. The transaction is expected to close by Q1 2025, subject to shareholder approval and regulatory clearances. The company projects post-close cash runway exceeding two years.
Coherus BioSciences (NASDAQ: CHRS) announced its participation in the 2024 Citi Global Healthcare Conference. Dr. Theresa LaVallee, Chief Development Officer, will be a panelist on the Novel Mechanisms in Oncology Panel scheduled for December 3, 2024, at 3:15 p.m. ET. The panel discussion will be available via webcast through the Investor Events and Presentations section of the Coherus website.
Coherus BioSciences (CHRS) reported Q3 2024 net revenue of $70.8 million, driven by strong growth in UDENYCA® and LOQTORZI® sales. UDENYCA net product sales reached $66.1 million, up 30% quarter-over-quarter and 100% year-over-year, maintaining 28% market share. LOQTORZI sales grew 54% to $5.8 million. The company reported a Q3 net loss of $10.8 million, or $(0.09) per share. Cash position stood at $97.7 million as of September 30, 2024. The company projects combined R&D and SG&A expenses for 2024 to be between $250-260 million.
Coherus BioSciences (NASDAQ: CHRS) has announced it will release its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company's management will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the results and provide a business update. Investors can access the conference call through pre-registration and join the webcast through the company's investor relations website. The financial results press release and related materials will be available before the call on the Coherus investor website.
Coherus BioSciences (NASDAQ: CHRS) reported Q2 2024 financial results and business updates. Key highlights:
- Net revenue of $65.0 million in Q2 2024
- UDENYCA net sales increased 60% year-over-year to $50.9 million
- LOQTORZI net sales of $3.8 million since January 2024 launch
- Phase 1 study of CHS-114 showed promising results in solid tumors
- Appointed Bryan McMichael as new CFO
- Divested YUSIMRY franchise for $40 million
- Net loss of $12.9 million or $(0.11) per diluted share in Q2 2024
- Cash and investments of $159.2 million as of June 30, 2024
- Projected 2024 R&D and SG&A expenses of $250-$265 million
Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced that it will release its second quarter 2024 financial results after market close on Thursday, August 8, 2024. The company's management team will host a conference call and webcast at 5:00 p.m. EDT on the same day to discuss the results and provide a general business update.
Investors and interested parties can pre-register for the conference call to receive dial-in information and a personal PIN. A live webcast will be available, and a replay will be accessible on the company's investor relations website. The press release containing the financial results and related materials will be available on the Coherus website before the start of the conference call.
On June 27, 2024, Coherus BioSciences (Nasdaq: CHRS) announced the divestiture of YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. (HKF) for $40 million in an all-cash deal. The transaction, completed on June 26, 2024, aligns with Coherus' strategic focus on oncology.
Meitheal Pharmaceuticals, a wholly owned subsidiary of HKF, will continue the commercialization of YUSIMRY in the U.S. Coherus plans to use the proceeds to strengthen its cash position and further its oncology initiatives.
Coherus' oncology portfolio includes LOQTORZI (toripalimab-tpzi), an FDA-approved PD-1 inhibitor, and the UDENYCA (pegfilgrastim-cbqv) franchise with three FDA-approved presentations, along with a clinical-stage immuno-oncology portfolio.
Coherus BioSciences (CHRS) has appointed Rita Karachun, CPA, CGMA, to its Board of Directors, effective May 31, 2024. Karachun, a seasoned financial expert with nearly four decades of experience, previously served as SVP and Global Controller at Merck. At Merck, she managed a global team responsible for the company's accounting and operational aspects. Coherus believes her extensive background in finance, accounting, and operational transformation will significantly benefit the company's strategic direction and pipeline advancement. CEO Denny Lanfear expressed confidence in Karachun's ability to contribute to Coherus's growth and transformation.
Coherus BioSciences (Nasdaq: CHRS) will present at the 2024 Jefferies Global Healthcare Conference on June 6, 2024, at 8:30 a.m. EDT/5:30 a.m. PDT.
Senior management will discuss the company's latest developments and strategies.
The presentation can be accessed via a webcast on the Coherus website, and it will be available for replay until July 7, 2024.
FAQ
What is the current stock price of Coherus Bioscien (CHRS)?
What is the market cap of Coherus Bioscien (CHRS)?
